Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry.

[1]  Deepak L. Bhatt,et al.  Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization , 2015, Journal of the American Heart Association.

[2]  P. Austin,et al.  Association of Heart Rate at Hospital Discharge With Mortality and Hospitalizations in Patients With Heart Failure , 2014, Circulation. Heart failure.

[3]  Laura G. Qualls,et al.  Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. , 2014, Journal of cardiac failure.

[4]  M. Metra.  Tachycardia after a heart failure hospitalization: another piece of the puzzle? , 2013, JACC. Heart failure.

[5]  C. Yancy,et al.  The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. , 2013, JACC. Heart failure.

[6]  J. Myers,et al.  Heart rate at rest, exercise capacity, and mortality risk in veterans. , 2013, The American journal of cardiology.

[7]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[8]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[9]  Laura G. Qualls,et al.  Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. , 2013, American heart journal.

[10]  S. Solomon,et al.  Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. , 2012, Journal of the American College of Cardiology.

[11]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[12]  K. Swedberg,et al.  Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) , 2010, European journal of heart failure.

[13]  C. O'connor,et al.  Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, American heart journal.

[14]  Jean-Claude Tardif,et al.  Resting heart rate in cardiovascular disease. , 2007, Journal of the American College of Cardiology.

[15]  C. O'connor,et al.  Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.

[16]  J. Butler,et al.  Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge , 2004 .

[17]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[18]  R S Paffenbarger,et al.  Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.